Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Wesley H. Self, Uriel Sandkovsky, Cavan Reilly, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 5, pp. 622-635
Open Access | Times Cited: 182

Showing 1-25 of 182 citing articles:

A living WHO guideline on drugs for covid-19
Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, et al.
BMJ (2020), pp. m3379-m3379
Open Access | Times Cited: 962
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Structural biology of SARS-CoV-2: open the door for novel therapies
Weizhu Yan, Yanhui Zheng, Xiao‐Tao Zeng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 241
Monoclonal antibody therapies against SARS-CoV-2
Daniele Focosi, Scott A. McConnell, Arturo Casadevall, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 11, pp. e311-e326
Open Access | Times Cited: 204
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 138
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Takuya Tada, Hao Zhou, Belinda M. Dcosta, et al.
EBioMedicine (2022) Vol. 78, pp. 103944-103944
Open Access | Times Cited: 137
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Thomas L Holland, Adit A. Ginde, Roger Paredes, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 10, pp. 972-984
Open Access | Times Cited: 99
Development of therapeutic antibodies for the treatment of diseases
Zeng Wang, Guoqing Wang, Huaqing Lu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 75
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Dennis R. Burton
Nature reviews. Immunology (2023) Vol. 23, Iss. 11, pp. 720-734
Open Access | Times Cited: 62
Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2
Bingqing Xia, Xiaoyan Pan, Rong‐Hua Luo, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 47
Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness
Wenhao Liu, Zehong Huang, Jin Xiao, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 184-184
Open Access | Times Cited: 20
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Daniele Focosi, Arturo Casadevall, Massimo Franchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 19
Sotrovimab: First Approval
Young‐A Heo
Drugs (2022) Vol. 82, Iss. 4, pp. 477-484
Open Access | Times Cited: 53
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
Ralph Rogers, Deborah Wentworth, Andrew Phillips, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 10, pp. 1401-1410
Open Access | Times Cited: 47
Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
Smaranda Gliga, Nadine Lübke, Alexander Killer, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. 408-415
Open Access | Times Cited: 46
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, et al.
Health Science Reports (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 38
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Jon Salmanton‐García, Francesco Marchesi, María Gomes da Silva, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101939-101939
Open Access | Times Cited: 24
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies
Fanchong Jian, Anna Z. Wec, Leilei Feng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 8
Structure-Based Discovery of the SARS-CoV-2 Main Protease Noncovalent Inhibitors from Traditional Chinese Medicine
Xiaojie Jin, Min Zhang, Beibei Fu, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 4, pp. 1319-1330
Closed Access | Times Cited: 7
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top